Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Rizzo

Showing results (1-10 of 381) with videos related to

Pageof 39
Sort By:
Thoracic Cancer|August 22, 2022
Bayesian analysis supports the role of neoadjuvant chemoradiation followed by surgery for resectable locoregional esophageal cancerAlessandro Rizzo
Expert Opinion on Investigational Drugs|June 28, 2021
Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option?Alessandro Rizzo
Cancer Treatment and Research Communications|April 2, 2021
The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancerAlessandro Rizzo
British Journal of Cancer|September 5, 2022
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debateAlessandro Rizzo
Future Oncology (London, England)|February 23, 2022
Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand?Alessandro Rizzo
Thoracic Cancer|April 3, 2023
Bayesian analysis supports the role of alectinib and ensartinib for ALK-positive non-small cell lung cancerAlessandro Rizzo
Medicina (Kaunas, Lithuania)|June 2, 2021
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR InhibitorsAlessandro Rizzo
Future Oncology (London, England)|July 15, 2021
Use of granulocyte colony-stimulating factor for adult cancer patients: current issues and future directionsAlessandro Rizzo
Expert Opinion on Investigational Drugs|February 25, 2021
Novel approaches for the management of biliary tract cancer: today and tomorrowAlessandro Rizzo
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 30, 2023
Bayesian analysis supports the role of apixaban for cancer patientsAlessandro Rizzo
Pageof 39

Showing results (1-10 of 381) with videos related to

Sort By:
Pageof 39
Thoracic Cancer|August 22, 2022
Bayesian analysis supports the role of neoadjuvant chemoradiation followed by surgery for resectable locoregional esophageal cancerAlessandro Rizzo
Expert Opinion on Investigational Drugs|June 28, 2021
Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option?Alessandro Rizzo
Cancer Treatment and Research Communications|April 2, 2021
The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancerAlessandro Rizzo
British Journal of Cancer|September 5, 2022
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debateAlessandro Rizzo
Future Oncology (London, England)|February 23, 2022
Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand?Alessandro Rizzo
Thoracic Cancer|April 3, 2023
Bayesian analysis supports the role of alectinib and ensartinib for ALK-positive non-small cell lung cancerAlessandro Rizzo
Medicina (Kaunas, Lithuania)|June 2, 2021
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR InhibitorsAlessandro Rizzo
Future Oncology (London, England)|July 15, 2021
Use of granulocyte colony-stimulating factor for adult cancer patients: current issues and future directionsAlessandro Rizzo
Expert Opinion on Investigational Drugs|February 25, 2021
Novel approaches for the management of biliary tract cancer: today and tomorrowAlessandro Rizzo
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 30, 2023
Bayesian analysis supports the role of apixaban for cancer patientsAlessandro Rizzo
Pageof 39